StoxAccretion Pharmaceuticals Limited
NSE: ACCPL · Unclassified
Ask the data
Instant answers about Accretion Pharmaceuticals Limited — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY25 | FY26 | |
|---|---|---|
| Revenue | 57.4 | 89.6 |
| EBITDA | 11.9 | 14.9 |
| Operating margin | 20.7% | 16.7% |
| Interest | 1.4 | 0.8 |
| Depreciation | 0.8 | 1.2 |
| Profit before tax | 9.8 | 13.1 |
| Tax | 3.0 | 3.4 |
| Net profit | 6.8 | 9.7 |
| EPS ₹ | 8.48 | 9.03 |
| Operating cash flow | 5.8 | -14.6 |
| Capex | 1.6 | 8.5 |
| Dividend paid | 0.0 | 0.0 |
| Total assets | 39.9 | 76.7 |
| Equity | 15.3 | 54.7 |
Half-yearly performance
last 5 half years · ₹ crore| H1 FY25* | H2 FY25 | H1 FY26 | H2 FY26 | H1 FY27 | |
|---|---|---|---|---|---|
| Revenue | 18.6 | 38.8 | 43.7 | 45.9 | 55.0 |
| Operating profit | 4.3 | 7.5 | 7.1 | 7.9 | 12.2 |
| Operating margin | 23.4% | 19.4% | 16.2% | 17.2% | 22.2% |
| Other income | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 |
| Interest | 0.7 | 0.7 | 0.4 | 0.5 | 0.7 |
| Depreciation | 0.4 | 0.4 | 0.4 | 0.8 | 0.9 |
| Profit before tax | 3.3 | 6.5 | 6.4 | 6.7 | 10.8 |
| Tax | 0.8 | 2.1 | 1.7 | 1.8 | 2.6 |
| Net profit | 2.5 | 4.3 | 4.8 | 4.9 | 8.2 |
| EPS ₹ | 3.18 | 5.30 | 4.61 | 4.42 | 7.38 |
| Revenue YoY | — | — | 135.5% | 18.2% | 25.8% |
| Profit YoY | — | — | 93.1% | 13.6% | 72.6% |
Returns & margins
trailing-twelve-month, per half year| H2 FY25 | H1 FY26 | H2 FY26 | H1 FY27 | |
|---|---|---|---|---|
| ROE | 44.4% | 19.5% | 17.7% | 20.9% |
| ROCE | 38.1% | 25.7% | 20.8% | 23.4% |
| Net margin | 11.8% | 11.0% | 10.8% | 13.0% |
| EBITDA margin | 20.7% | 17.7% | 16.7% | 19.9% |
| Debt / equity | 0.92 | 0.17 | 0.23 | 0.27 |
| Interest coverage | 7.78 | 12.60 | 16.39 | 16.50 |
| Asset turnover | 1.44 | 1.40 | 1.17 | 1.16 |
Balance sheet
equity vs borrowings over time · ₹ crore| MAR '25 | SEP '25 | MAR '26 | SEP '26 | |
|---|---|---|---|---|
| Share capital | 8.2 | 11.1 | 11.1 | 11.1 |
| Other equity / reserves | 7.1 | 35.5 | 43.6 | 51.8 |
| Total equity | 15.3 | 46.6 | 54.7 | 62.9 |
| Borrowings | 14.1 | 7.9 | 12.3 | 16.7 |
| Current liabilities | 23.2 | 11.5 | 20.8 | 18.9 |
| Non-current liabilities | 1.4 | 1.0 | 1.1 | 5.6 |
| Total assets | 39.9 | 59.1 | 76.7 | 87.4 |
| Property, plant & equipment | 6.1 | 8.7 | 13.2 | 13.4 |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventories | 20.6 | 22.8 | 28.4 | 30.0 |
| Receivables | 11.7 | 21.9 | 22.4 | 32.0 |
| Cash & equivalents | 0.1 | 0.2 | 4.0 | 2.1 |
Cash flow
annual · ₹ crore · line = free cash flow| FY25 | FY26 | |
|---|---|---|
| Cash from operations | 5.8 | -14.6 |
| Cash from investing | -1.6 | -8.5 |
| Cash from financing | -4.3 | 27.1 |
| Capex | 1.6 | 8.5 |
| Free cash flow | 4.2 | -23.1 |
| Dividends paid | 0.0 | 0.0 |
Where the assets sit
Sep '26 · ₹ crorePeer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Accretion Pharmaceuticals Limited | 225 | 202.50 | 17.2 | 3.58 | 20.9% |
StoxGud checklist: Bullish setup · 10/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
FAQs
What is the share price of Accretion Pharmaceuticals Limited?
Accretion Pharmaceuticals Limited (ACCPL) closed at ₹202.50 on NSE on 06 Nov 2026.
What is the market cap of Accretion Pharmaceuticals Limited?
₹225 crore at the latest close.
What is the P/E ratio of Accretion Pharmaceuticals Limited?
17.2, on trailing-twelve-month earnings from its filings.
How fast is Accretion Pharmaceuticals Limited growing?
Accretion Pharmaceuticals Limited: Latest-half-year revenue is up 25.8% year on year, profit up 72.6%.
How profitable is Accretion Pharmaceuticals Limited?
On a trailing-twelve-month basis return on equity is 20.9%, return on capital employed 23.4%, operating margin 19.9%, net margin 13.0%.
How much debt does Accretion Pharmaceuticals Limited have?
Accretion Pharmaceuticals Limited is lightly geared: debt to equity is 0.27 with borrowings of ₹17 cr against cash of ₹2 cr (balance sheet of 2026-09-30). Operating profit covers interest 16.5 times.
Financials parsed from Accretion Pharmaceuticals Limited's own XBRL filings to NSE (standalone), ₹ crore unless marked. Half-yearly from H1 FY25, annual from FY25, balance sheet from Mar '25. * = derived (full year minus the other half). This company is on NSE's SME platform and reports results half-yearly. Information only, not investment advice.